Numan expands into menopause care
Numan
This expansion turns Numan from a set of male condition clinics into a broader hormonal care platform, which matters because menopause and hormone management look much more like long duration care than one off treatment. The same app flow, blood testing, prescribing, pharmacy fulfillment, coaching, and follow up that works for weight loss and testosterone can be reused for women in their 40s and 50s, with more frequent monitoring and higher potential lifetime spend.
-
Numan already runs the exact machinery needed for this category. Patients complete questionnaires or upload labs, clinicians review eligibility, prescriptions and test kits ship directly, and follow up happens through in app chat, coaching, and scheduled biomarker reviews. Menopause care fits that workflow naturally because dosing and symptom management change over time.
-
There is a clear playbook for monetizing women’s health in digital care. Maven built a large employer focused business around fertility, maternity, pediatrics, and menopause, reaching $268M revenue in 2024. That shows women’s health is not just a consumer add on, it can support recurring contracts and broader care bundles.
-
A close analogue is Hone Health, which also started in men’s hormones and then launched women’s hormone therapy in January 2025. By September 2025, Hone reached $113.5M ARR, with growth accelerating after adding women’s care, weight loss, and longevity products. The pattern is that hormone clinics grow faster when they expand from one sex and one condition into a multi line platform.
The next step is for Numan to package hormonal health as a repeatable care pathway, not a one time product launch. If it executes, women’s health can become the second pillar next to metabolic care, deepen employer distribution, and make Numan harder to compete with because customers will rely on one platform for testing, prescribing, coaching, and ongoing symptom management across multiple life stages.